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Table 1
A panel of different types of potential protein biomarkers of OA
Protein name Symbol Ratio
UZ/N
p value Ratio
WZ/N
p value OA biomarker
type
Annexin A5 4,8753 0,0387 1,2706 0,5217 Early
Chitinase-3-like
protein 2
CHI3L2 4,8306 0 0,871 0,147 Early
Phospholipase A2 4,4463 0,0308 0,3373 0,2114 Early
Hyaluronan and
proteoglycan
link protein 1
HPLN1 2,3768 0 1,0375 0,1073 Early
Apolipoprotein A-I APOA1 2,884 0,1025 7,7268 0 Late
Apolipoprotein E APOE 1,5417 0,9203 4,6989 0,0248 Late
Complement C3 C3 0,9908 0,8541 2,6303 0,0097 Late
Complement C4-B C4B 1,2942 0,7081 2,3121 0,0151 Late
Haptoglobin HPT 6,9823 0,0432 14,3219 0,0001 Progression
Histone H4 H4 2,355 0,0196 7,2444 0,0198 Progression
Tenascin TENA 9,6383 0,0001 27,7971 0 Progression
TGF-b-induced
protein ig-h3
BIGH3 7,7268 0 11,695 0 Progression
Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489S426discs/zone were placed into 96 wells plates and incubated (37 C/5%
CO2) in serum-free DMEM up to 6 days. Conditioned media from each
condition were collected at day 1, 3 and 6. Selective extraction of
endogenous peptides was accomplished by combining ultraﬁltration
and solid phase extraction. Then, the peptides were directly analyzed by
nano reversed-phase liquid chromatography (RP-LC) in an Easy nLC II
system coupled to an ion trap LTQ Orbitrap Velos Pro mass spec-
trometer (Thermo Scientiﬁc). Peptide/protein identiﬁcations were
searched against database (human_fasta) using the SEQUEST algorithm
(Proteome Discoverer 1.3, Thermo Scientiﬁc).
Results: After optimization steps of the procedure, day 3was selected as
the best point for our proteomic analysis to compare the peptide pro-
ﬁles from UZ and WZ, showing the highest number of unique peptides/
proteins and the lowest serum contamination. Globally, this study led to
the identiﬁcation of a panel of 262 peptides corresponding to 36 pro-
teins that were differentially released from the UZ and WZ in OA car-
tilage. 60 peptides (corresponding to 20 proteins) were detected only in
the UZ (early biomarkers), while 18 peptides (corresponding to 5 pro-
teins) only in the WZ (late biomarkers). Finally, 11 proteins were
detected in both zones; however also in this case the number of pep-
tides was higher in the UZ than in the WZ. These results suggest that
cartilage from the UZ shows a protein turnover rate higher than carti-
lage from theWZ, thus facilitating the discovery of OA biomarkers in an
early stage of the disease, when radiographic signs are not yet detect-
able. Data mining revealed that most of the identiﬁed proteins were
cartilage ECM proteins or proteins with well-established matrix func-
tions, such as collagens and proteoglycans, thus indicating the high
cartilage-speciﬁc biomarker concentration present in our samples.
Some of these proteins have been associated with OA pathology before
(collagen II, proteoglycan 4, tubulin, vimentin), while others are
described here for the ﬁrst time (augurin, salivary acidic proline-rich
phosphoprotein 1/2, dermcidin).
Conclusions: Our results clearly indicate that proﬁling of peptides from
cartilage secretome represents a promising alternative in the ﬁeld of OA
biomarker discovery. In this study we highlight its potential application
as novel OA biomarker source both for early disease detection (early
biomarkers) and for monitoring disease progression (late biomarkers).
Further investigations of these peptides on biological ﬂuids will assess
their biomarker usefulness.
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A NOVEL PANEL OF CARTILAGE SECRETED PROTEINS WITH A
POTENTIAL OA BIOMARKER VALUE
L. Lourido, V. Calamia, P. Fernandez-Puente, J. Mateos, B. Rocha,
C. Fernandez-Costa, F.J. Blanco, C. Ruiz-Romero. Rheumatology Div.,
Proteomics Group-ProteoRed/ISCIII, INIBIC-CHUAC, A Coru~na, Spain
Purpose: Osteoarthritis (OA) is characterized by the progressive loss
of cartilage structural extracellular matrix (ECM) components,
mainly collagenous and non-collagenous proteins. The release of
these proteins from the tissue can vary according to the stage of the
disease. Characterization of molecular differences between
cartilage subtypes will provide a background for a better under-
standing of OA onset and progression. The aim of this study was to
perform a quantitative proteomics approach to identify and quantify
those proteins released from normal (N) and OA human articular
cartilages.
Methods: Tissue explants were obtained from the dissection of 4 N
and 4 OA cartilages, both from femoral heads and tibial condyles.
Among the OA samples, we differentiated the wounded zones (WZ)
from those corresponding to the area adjacent to the lesion, or
unwounded zones (UZ). The study was approved by the local ethical
committee. Cartilage shavings from each donor were cut into 6 mm
discs and ﬁve discs/donor were placed into 96-well plates and
incubated during 6 days (37C/5% CO2). The conditioned media from
each condition were collected and their proteins were digested with
trypsin. Each peptide mixture was labelled with different isobaric
tags using the iTRAQ reagents (ABSciex). Then, labelled peptides of
the different conditions were mixed, desalted and separated by liq-
uid chromatography (LC). The resulting fractions were grouped and
resolved by reversed-phase nano-LC coupled to mass spectrometry
(MS). The identiﬁcation and relative quantiﬁcation of the proteins
was carried out with Protein Pilot 3.0 software.
Results: Globally we were able to identify 402 proteins released from
the cartilage explants. Measurement of the different iTRAQ tagsintensities allowed the relative quantiﬁcation of almost all of them (n
¼ 390). After statistical analysis we found 104 secreted proteins
showing differences in abundance (0.8 ratio 1.2, p 0.05)
between the different OA zones (WZ and UZ) and N samples. We
classiﬁed them into 3 sets of proteins: a ﬁrst group of 11 proteins
modulated speciﬁcally in UZ sample; a second group of 38 proteins
altered only in WZ samples, and ﬁnally a third group of 55 proteins
modiﬁed in both OA zones. Proteins increased in UZ samples are
classiﬁed as early OA biomarkers, while proteins increased only in
WZ samples are deﬁned as late OA biomarkers (Table 1). Proteins
showing a gradual increase among OA samples are indicated as
progression biomarkers (Table 1). Although some of these proteins
had a previously reported putative biomarker value for OA, most of
them are novel candidates of the disease onset (the ﬁrst group) and
progression (the second and third groups). Interestingly, when we
compared these results with those obtained from cartilage tissue
extracts we found that most of the proteins increased in OA cartilage
secretomes (like HPLN1, TENA, and BIGH3) are decreased in cartilage
proteomes and viceversa. Furthermore, some of these modulations
conﬁrmed the results obtained in OA serum in a previous work by
our group (e.g. APOE, C3, and HPT).
Conclusions: We describe a novel panel of cartilage secreted proteins
with potential biomarker value. This panel is now being explored in
biological ﬂuids (synovial ﬂuid and serum) for the development of early
diagnosis and/or anti-OA therapy monitoring strategies.Regenerative medicine
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CHONDROGENESIS OF HUMAN SYNOVIUM-DERIVED MESENCHYMAL
STEM CELLS INDUCED BY KARTOGENIN AND TRANSFORMING
GROWTH FACTORS
D. Shi, X. Xu, Q. Jiang. Sports Med. and Adult Reconstruction, Nanjing,
China
Purpose: To investigate if small molecule compound Kartogenin (KGN)
can direct the differentiation of human synovium derivedmesenchymal
stem cells (SMSCs) into chondrocytes or increase the chondrogenic
potential of tranforming growth factors.
Methods: Human SMSCs were isolated from synovial membrane tissue
harvested from 6 donors when they underwent total knee arthroplasty.
5  105 cells were centrifuged to form pellets and then incubated in
control medium or chondrogenic medium. The chondrogenic medium
was consisted of transforming growth factors with or without addition
of KGN. The group inwhich pellets induced only by KGNwas also setted.
We also designed a group in which SMSCs were induced ﬁrst with TGF-
b3 for 1 week and then with KGN for 2 weeks. Pellets were induced for
21 days. Pellets size, hematoxylin and eosin staining, immunohis-
tochemical staining for collagen type II, and cartilage speciﬁc gene
epression were used to measure chondrogenic ability.
